Merck introduces new service for the biotech field
Adaptive approach to cell line development, analytics and clone selection for emerging biotechs and start-ups. Merck has launched its Plug & Play Upstream Development Service to help emerging biotech and start-up companies optimize the cost and speed of advancing their molecule to the clinical stage. With 60 percent of drugs in the pipeline today being developed by emerging biotech companies, Merck’s tailored, streamlined service is poised to have a significant impact on drug development efficiency. In the early stages of upstream development, cell line development and analytical development occur in parallel, allowing molecules to progress faster. For customers looking to progress at an even faster speed, Merck offers its fast-track process by running process development and clone development steps in parallel, balancing speed and risk without sacrificing quality.